Janux Therapeutics JANX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$114.48M-47.3% | -$113.63M-64.7% | -$101.9M-68.3% | -$105.64M-140% | -$77.74M-39.8% | ||
| $1.98M-3.3% | $2.03M-1.5% | $2.07M-0.3% | $2.08M+0.6% | $2.05M+0.6% | ||
| $38.79M+1.8% | $40.22M+21.8% | $36.96M+18.3% | $43.3M+112% | $38.1M+89.0% | ||
| —— | —— | —— | —— | —— | ||
| $1M+149% | $977K-38.3% | $867K+146% | $2.21M+471% | $403K+660% | ||
| —— | —— | —— | —— | —— | ||
| $1.15M+330% | -$276K-174% | -$196K-139% | $53K— | $268K— | ||
| $46.27M+4,860% | $0+100% | $0+100% | -$94K+98.3% | -$972K+81.9% | ||
| -$77.55M-68.6% | -$82.24M-87.7% | -$70.42M-90.4% | -$59.79M-28.7% | -$46M+10.7% | ||
| $945K+77.3% | $1.04M+191% | $979K+17.7% | $911K-28.7% | $533K-69.8% | ||
| $446.68M-32.7% | $705.22M+49.9% | $605.98M+26.3% | $520.47M-10.8% | $663.33M+56.4% | ||
| $495.32M+176% | $405.28M+90.4% | $310.36M+55.4% | $229.16M-0.2% | $179.19M-35.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $7.94M-98.0% | $4.95M-99.3% | $388.65M+18.7% | $389.81M+1.9% | $391.62M+3.0% | ||
| -$25.86M+81.4% | -$382.22M-193% | $21.64M— | $37.78M— | -$139.06M— | ||
| $15.98M+22.7% | $17.57M+66.0% | $16.98M+74.7% | $15.25M+70.8% | $13.02M+67.0% | ||
| $1.98M-3.3% | $2.03M-1.5% | $2.07M-0.3% | $2.08M+0.6% | $2.05M+0.6% | ||
| $46.27M+4,860% | $0+100% | $0+100% | -$94K+98.3% | -$972K+81.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $1.4M-34.6% | $2.81M+7.6% | ||
| $495.32M+176% | $405.28M+90.4% | $310.36M+55.4% | $229.16M-0.2% | $179.19M-35.9% | ||
| —— | —— | —— | —— | —— | ||
| -$212K— | $0— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $943K— | $707.25K— | —— | —— | ||
| -$78.49M-68.7% | -$83.28M-88.5% | -$71.4M-88.8% | -$60.7M-27.1% | -$46.53M+12.6% | ||
| -$78.49M-68.7% | -$83.28M-88.5% | -$71.4M-88.8% | -$60.7M-27.1% | -$46.53M+12.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Janux Therapeutics generate?
- Janux Therapeutics (JANX) generated -$77.5M in operating cash flow over the trailing twelve months.
- What is Janux Therapeutics's free cash flow?
- After $945.0K of capital expenditures, Janux Therapeutics's free cash flow was -$78.5M over the trailing twelve months, down 68.7% year over year.
- Where does Janux Therapeutics's cash flow data come from?
- Every line is extracted from Janux Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
